Related Experiment Video
Updated: May 13, 2025

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
The patterns of systemic metastasis in major salivary gland cancer and therapeutic implications
Subi Oh1, Younghac Kim1, Hyojun Kim1
1Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Background:
This study aimed to investigate the patterns of metastatic spread of salivary gland cancer (SGC) and their therapeutic implications. Patterns of systemic metastasis, post-metastasis survival, and risk factors have not been defined clearly in SGC, and the validity of the concept of oligometastasis in SGC has never been explored.
Methods:
This was a retrospective study of SGC patients with systemic metastasis (N = 199). The primary outcome was post-metastasis disease-specific survival, and multivariable survival analyses for risk factors were performed. The patients were divided into three pathology groups, adenoid cystic carcinomas (ACCs), non-ACC high-grade tumors, and non-ACC intermediate or low-grade tumors.
Results:
Median survival was 28.9 months after diagnosis of systemic metastasis. Only 30 % of patients had oligometastasis (≤ 3 metastatic lesions and ≤ 2 involved organs), and polymetastasis was observed in 70 % (33.7 % single organ polymetastasis and 36.2 % multi-organ polymetastasis). Poor patient performance status, shorter metastasis-free interval, non-ACC high-grade tumor, concurrent local disease, and multi-organ polymetastasis were identified as independent risk factors for post-distant metastasis survival. Of note, SGC patients with oligometastasis and single organ polymetastasis showed similar survival outcomes. Systemic chemotherapy did not improve post-metastasis survival of SGC patients significantly. However, HER-2 targeted therapy combined with chemotherapy extended post-metastasis survival in c-erb-B2 expressing tumors.
Conclusions:
Systemic metastasis into multiple organs is a common pattern of SGC metastasis, and significantly affects patient survival. Tumor biology-based therapy should be further sought for improving post-metastasis outcomes of SGC patients.
Insights
Salivary gland cancer (SGC) commonly metastasizes to multiple organs, impacting survival. Oligometastasis is rare, and targeted therapies show promise for specific SGC subtypes.
Area of Science:
- Oncology
- Cancer Metastasis Research
Background:
- Salivary gland cancer (SGC) metastasis patterns and survival are poorly understood.
- Oligometastasis in SGC has not been previously investigated.
Purpose of the Study:
- To investigate SGC metastasis patterns and their impact on survival.
- To identify risk factors for post-metastasis survival in SGC.
- To explore the concept of oligometastasis in SGC.
Main Methods:
- Retrospective analysis of 199 SGC patients with systemic metastasis.
- Categorization into adenoid cystic carcinomas (ACCs), non-ACC high-grade, and non-ACC intermediate/low-grade tumors.
- Multivariable survival analyses to identify risk factors.
Main Results:
- Median survival post-metastasis was 28.9 months.
- Oligometastasis observed in 30% of patients; polymetastasis in 70%.
- Independent risk factors identified: poor performance, shorter metastasis-free interval, high-grade non-ACC tumors, concurrent local disease, multi-organ polymetastasis.
- HER-2 targeted therapy improved survival in c-erb-B2 positive tumors.
Conclusions:
- Multi-organ metastasis is common in SGC and significantly impacts survival.
- Oligometastasis and single-organ polymetastasis had similar survival outcomes.
- Further research into tumor biology-based therapies is crucial for improving SGC outcomes.
More Related Videos
07:38Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics
Published on: May 17, 2019
07:25Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023